Clinical Trials List
2022-09-01 - 2028-12-31
Phase III
Recruiting4
-
-
Sponsor
-
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/09/15
Investigators and Locations
Co-Principal Investigator
- 王秀慈 Division of Hematology & Oncology
- Che-Hung Lin Division of Hematology & Oncology
- Chen-Yuan Lin Division of Hematology & Oncology
- Ching-Chan Lin Division of Hematology & Oncology
- Ming-Yu Lien Division of Hematology & Oncology
- Chi-Ching Chen Division of Hematology & Oncology
- Tzu-Ting Chen Division of Hematology & Oncology
- Yu-Min Liao Division of Hematology & Oncology
- 鄭富銘 Division of Hematology & Oncology
- 王幸婷 Division of Hematology & Oncology
- 陳珈妤 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- YU-HSUAN SHIH Division of Hematology & Oncology
- PO-HSIEN LI Division of Hematology & Oncology
- ZHENG-WEI ZHOU Division of Hematology & Oncology
- HSIN-CHEN LIN Division of Hematology & Oncology
- Tsung -Chih Chen Division of Hematology & Oncology
- PO-WEI LIAO Division of Hematology & Oncology
- 滕傑林 Division of Hematology & Oncology
- 鄧齡喬 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- HSUAN JEN SHIH Division of Hematology & Oncology
- Ming-Chung Kao Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Sheng-chieh Chou Division of Hematology & Oncology
- 林耘曲 Division of Hematology & Oncology
- MING YAO Division of Hematology & Oncology
- 柯紀綸 Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Study Contacts
- -
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Exclusion Criteria
The Estimated Number of Participants
-
Taiwan
70 participants
-
Global
1126 participants
